» Articles » PMID: 35869079

A Multi-omic Dissection of Super-enhancer Driven Oncogenic Gene Expression Programs in Ovarian Cancer

Overview
Journal Nat Commun
Specialty Biology
Date 2022 Jul 22
PMID 35869079
Authors
Affiliations
Soon will be listed here.
Abstract

The human genome contains regulatory elements, such as enhancers, that are often rewired by cancer cells for the activation of genes that promote tumorigenesis and resistance to therapy. This is especially true for cancers that have little or no known driver mutations within protein coding genes, such as ovarian cancer. Herein, we utilize an integrated set of genomic and epigenomic datasets to identify clinically relevant super-enhancers that are preferentially amplified in ovarian cancer patients. We systematically probe the top 86 super-enhancers, using CRISPR-interference and CRISPR-deletion assays coupled to RNA-sequencing, to nominate two salient super-enhancers that drive proliferation and migration of cancer cells. Utilizing Hi-C, we construct chromatin interaction maps that enable the annotation of direct target genes for these super-enhancers and confirm their activity specifically within the cancer cell compartment of human tumors using single-cell genomics data. Together, our multi-omic approach examines a number of fundamental questions about how regulatory information encoded into super-enhancers drives gene expression networks that underlie the biology of ovarian cancer.

Citing Articles

Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling.

Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B Cell Genom. 2025; 5(2):100765.

PMID: 39914387 PMC: 11872555. DOI: 10.1016/j.xgen.2025.100765.


Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies.

Ji Y, Li B, Lin R, Yuan J, Han Y, Du Y J Transl Med. 2025; 23(1):98.

PMID: 39838405 PMC: 11753147. DOI: 10.1186/s12967-025-06098-x.


Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer.

Lin S, Nguyen L, McMellen A, Leibowitz M, Davidson N, Spinosa D Mol Diagn Ther. 2024; 29(2):145-151.

PMID: 39557776 DOI: 10.1007/s40291-024-00757-3.


FOSL1 is a key regulator of a super-enhancer driving TCOF1 expression in triple-negative breast cancer.

He Q, Hu J, Huang H, Wu T, Li W, Ramakrishnan S Epigenetics Chromatin. 2024; 17(1):34.

PMID: 39523372 PMC: 11552368. DOI: 10.1186/s13072-024-00559-1.


Super-Enhancer Driven LIF/LIFR-STAT3-SOX2 Regulatory Feedback Loop Promotes Cancer Stemness in Head and Neck Squamous Cell Carcinoma.

Li J, Wang Y, Wang Z, Wei Y, Diao P, Wu Y Adv Sci (Weinh). 2024; 11(40):e2404476.

PMID: 39206755 PMC: 11516160. DOI: 10.1002/advs.202404476.


References
1.
Grant C, Bailey T, Noble W . FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011; 27(7):1017-8. PMC: 3065696. DOI: 10.1093/bioinformatics/btr064. View

2.
Franco H, Nagari A, Malladi V, Li W, Xi Y, Richardson D . Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res. 2017; 28(2):159-170. PMC: 5793780. DOI: 10.1101/gr.226019.117. View

3.
Kim T, Shiekhattar R . Architectural and Functional Commonalities between Enhancers and Promoters. Cell. 2015; 162(5):948-59. PMC: 4556168. DOI: 10.1016/j.cell.2015.08.008. View

4.
Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

5.
Ma Q, Yang F, Mackintosh C, Jayani R, Oh S, Jin C . Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells. Cell Rep. 2020; 31(3):107532. DOI: 10.1016/j.celrep.2020.107532. View